Nycomed Instantyl nasal spray approved in Europe

Published: 5-Jul-2011
Regulatory

Single-dose nasal spray for breakthrough pain in cancer patients


The European Commission has approved Nycomed's Instanyl (fentanyl) in a single-dose nasal spray for the treatment of breakthrough pain in cancer patients.

The fast acting nasal opioid was first approved in a multi-dose nasal spray in 2009 and Swiss pharmaceutical firm Nycomed hopes the new version will be more flexible for patients and ease the management of dose titration and modification.

Guido Oelkers, executive VP at Nycomed, said: ‘Development of the Instanyl single-dose nasal spray further demonstrates Nycomed's commitment to innovation in areas of clear medical need.

‘Over half a million cancer patients are suffering from breakthrough pain in Europe. The Instanyl single-dose nasal spray will add flexibility to the managing of their pain.’

The single-dose nasal spray will be available in European countries from September in dose strengths of 50µg, 100µg, and 200µg.

See more

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Read more
Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP
Regulatory

Takeda announces its intention to acquire TiGenix

Takeda Pharmaceutical has announced its intention to launch a voluntary conditional takeover bid on TiGenix, an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions
Regulatory

Multiple myeloma – ixazomib

An orally available therapeutic is being developed by Takeda
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Regulatory

Inflammatory bowel disease – vedolizumab

Although Crohn’s disease and ulcerative colitis are the two most common forms of inflammatory bowel disease, treatment options remain less than ideal
Regulatory

Anticancer agent – orteronel

Because it is often diagnosed late, prostate cancer is already metastatic in around one in seven of all patients
Subscribe now